

# Henry Lik Yuen Chan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6123369/henry-lik-yuen-chan-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

456 papers	33,075 citations	93 h-index	167 g-index
488 ext. papers	39,357 ext. citations	7 avg, IF	7.06 L-index

#	Paper	IF	Citations
456	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100441	10.3	1
455	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. <i>GastroHep</i> , <b>2022</b> , 2022, 1-13	1	
454	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> , 55, 616-617	6.1	0
453	ACE inhibitors prevent liver-related events in non-alcoholic fatty liver disease.. <i>Hepatology</i> , <b>2021</b> ,	11.2	5
452	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 321-331	6.1	5
451	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 984-993	0.7	10
450	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , <b>2021</b> ,	13.3	9
449	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> ,	6.9	2
448	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. <i>Hepatology Communications</i> , <b>2021</b> ,	6	6
447	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1950-1958.e7	6.9	8
446	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2161-2171.e5	6.9	36
445	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1212-1223	6	1
444	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , <b>2021</b> , 11, 5416	4.9	2
443	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab205	1	2
442	Hepatitis B Core-Related Antigen: From Virology to Clinical Application. <i>Seminars in Liver Disease</i> , <b>2021</b> , 41, 182-190	7.3	1
441	Debate settled for elevated alanine aminotransferase in hepatitis B?. <i>Lancet Infectious Diseases</i> , <b>2021</b> , 21, 750-751	25.5	
440	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , <b>2021</b> , 74, 1750-1765	11.2	12

439	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , <b>2021</b> , 70, 733-742	19.2	65
438	Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. <i>Hepatology</i> , <b>2021</b> , 73, 1652-1670	11.2	4
437	Letter to the Editor: Use of Pregenomic Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen to Predict Cure of Hepatitis B Virus Infection. <i>Hepatology</i> , <b>2021</b> , 73, 870	11.2	0
436	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong-A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e466-e475	11.6	13
435	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 84, 68-73	3.9	1
434	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1274-1283	0.7	7
433	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> ,	12.7	8
432	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00300	4.2	4
431	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00324	4.2	4
430	Questionnaire survey on knowledge, attitudes, and behaviour towards viral hepatitis among the Hong Kong public. <i>Hong Kong Medical Journal</i> , <b>2021</b> ,	0.7	2
429	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> , 27, 499-509	6.9	0
428	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , <b>2021</b> , 3, 261-269	1	
427	Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. <i>Hepatology</i> , <b>2021</b> , 74, 1795-1808	11.2	3
426	Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , <b>2021</b> , 67, 1492-1502	5.5	2
425	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , <b>2021</b> , 4, e352	2.2	
424	Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 660-666	11.6	13
423	Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 2210-2219	4	8
422	HBV variants are common in the immune-tolerant phase of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1061-1070	3.4	4

421	Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page". <i>Journal of Hepatology</i> , <b>2020</b> , 73, 729-730	13.4	
420	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , <b>2020</b> , 50, 1024-1031	5.1	13
419	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 867-875	0.7	13
418	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 899-908	6.9	7
417	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. <i>Cancer Discovery</i> , <b>2020</b> , 10, 664-673	24.4	42
416	Modelling NAFLD disease burden in four Asian regions-2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 801-811	6.1	31
415	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 1610-1618	4	2
414	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 406-417	18.8	22
413	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 441-453	18.8	45
412	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , <b>2020</b> , 72, 1230-1241	11.2	20
411	Unresolved issues of immune tolerance in chronic hepatitis B. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 3836-3839	3.9	5
410	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 128	3	4
409	hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study. <i>Journal of Infectious Diseases</i> , <b>2020</b> ,	7	5
408	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 904-914	3.4	6
407	Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1399-1406	6.1	5
406	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , <b>2020</b> , 92, 1206-1213	19.7	1
405	RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , <b>2020</b> , 72, 19-31	11.2	47
404	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. <i>Hepatology Communications</i> , <b>2020</b> , 4, 8-20	6	18

403	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2843-2845.e2	6.9	8
402	The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. <i>Liver International</i> , <b>2020</b> , 40, 549-557	7.9	6
401	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 847-854	13.4	26
400	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2020</b> , 40, 581-589	7.9	33
399	Complex genetic encoding of the hepatitis B virus on-drug persistence. <i>Scientific Reports</i> , <b>2020</b> , 10, 15574-9	4.9	3
398	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 7052-7061	4.8	5
397	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 776-787	18.8	51
396	Detection and characterization of jagged ends of double-stranded DNA in plasma. <i>Genome Research</i> , <b>2020</b> , 30, 1144-1153	9.7	23
395	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , <b>2020</b> , 2, 100152	10.3	8
394	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <i>Hepatology</i> , <b>2020</b> , 71, 444-455	11.2	19
393	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , <b>2020</b> , 158, 215-225.e6	13.3	94
392	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , <b>2020</b> , 69, 1116-1126	19.2	12
391	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 57-66	13.4	25
390	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 2202-2209	4	3
389	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , <b>2019</b> , 68, 2057-2064	19.2	65
388	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. <i>Hepatology</i> , <b>2019</b> , 70, 971-981	11.2	18
387	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1641-1647	4	7
386	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1509-1517	6.1	7

385	Towards finite oral antiviral treatment for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 260-262	18.8	2
384	Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 133-140	1.6	8
383	Reply to: "NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter". <i>Journal of Hepatology</i> , <b>2019</b> , 70, 1304	13.4	
382	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. <i>Gastroenterology</i> , <b>2019</b> , 156, 1392-1403.e7	13.3	73
381	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 538-544	18.8	29
380	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1969-1979	11.6	7
379	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , <b>2019</b> , 29, 418-427	9.7	81
378	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 241-248	4	22
377	Gastrointestinal disease burden and mortality: A public hospital-based study from 2005 to 2014. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 124-131	4	18
376	Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , <b>2019</b> , 9, 10529	4.9	7
375	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1037-1048	6.1	27
374	Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 4715-4726	5.6	7
373	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 916-928	0.7	27
372	The changing epidemiology of liver diseases in the Asia-Pacific region. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 57-73	24.2	116
371	Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. <i>Liver International</i> , <b>2019</b> , 39, 271-279	7.9	15
370	Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 126-135	3.4	12
369	Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 501-506	4	3
368	Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. <i>Liver International</i> , <b>2019</b> , 39, 494-502	7.9	1

367	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 361-370	13.4	80
366	96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 672-681	13.4	180
365	Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 730-737	6.1	42
364	Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3. <i>Hepatology</i> , <b>2018</b> , 67, 2302-2319	11.2	8
363	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 765-773.e2	6.9	29
362	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1278-1284	11.6	27
361	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 383-403	18.8	702
360	Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1306-1316	6.1	5
359	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 484-491	4	22
358	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 70-85	4	211
357	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 86-98 <sup>4</sup>		71
356	Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 228-235	3.4	9
355	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory-wide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 934-941	4	7
354	A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: A randomized trial. <i>Liver International</i> , <b>2018</b> , 38, 636-644	7.9	23
353	Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. <i>FASEB Journal</i> , <b>2018</b> , 32, 37-51	0.9	47
352	A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 547-555	6.1	21
351	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	27
350	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1429-1437	3.4	14

349	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , <b>2018</b> , 38, 1911-1919	7.9	8
348	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 1349-1356	13.4	96
347	Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 3487-3497	4	28
346	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 984-992	6.1	37
345	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 1239-1249	5.5	47
344	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , <b>2018</b> , 38, 1179-1187	7.9	16
343	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , <b>2018</b> , 52, 347-352	3	15
342	Improvements in the management of chronic hepatitis B virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 1153-1166	4.2	6
341	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1629-1638	0.7	17
340	Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E10925-E10933	11.5	73
339	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 793-802	13.4	45
338	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199198	3.7	4
337	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. <i>Hepatology</i> , <b>2017</b> , 65, 54-64	11.2	160
336	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , <b>2017</b> , 65, 1840-1850	11.2	51
335	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 161-176	18.8	1196
334	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1453-1460.e1	6.9	20
333	Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1213-1224	6.1	17
332	Tenofovir Alafenamide: A Review in Chronic Hepatitis B. <i>Drugs</i> , <b>2017</b> , 77, 1017-1028	12.1	26

331	Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 175-182	6.1	40
330	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1071-1078	4	5
329	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 577-584	13.4	80
328	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 447-456	6.1	73
327	International incidence and mortality trends of liver cancer: a global profile. <i>Scientific Reports</i> , <b>2017</b> , 7, 45846	4.9	152
326	Reply to: "Serum HBsAg kinetics in clinical prediction". <i>Journal of Hepatology</i> , <b>2017</b> , 67, 193-194	13.4	
325	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1363-1369	4	34
324	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1812-1823	0.7	49
323	Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 1001-1010	6.1	37
322	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	216
321	Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance". <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	
320	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	47
319	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	49
318	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 617-627	6.1	94
317	Strategies to manage hepatitis C virus infection disease burden-Volume 4. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24 Suppl 2, 44-63	3.4	13
316	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24 Suppl 2, 25-43	3.4	19
315	Historical epidemiology of hepatitis C virus in select countries-volume 4. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24 Suppl 2, 8-24	3.4	26
314	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 902-908	13.4	84

313	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 667-676	4	87
312	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 398-411	13.4	191
311	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1230-1233	4	14
310	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , <b>2017</b> , 65, 1145-1155	11.2	135
309	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 506-514	4	26
308	Combination of Tenofovir Disoproxil Fumarate and Peginterferon $\alpha$ Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , <b>2016</b> , 150, 134-144.e10	13.3	219
307	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , <b>2016</b> , 65, 1359-68	19.2	271
306	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , <b>2016</b> , 69, 971-984	7.3	15
305	Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 802-13	6.1	28
304	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , <b>2016</b> , 64, 34-46	11.2	65
303	Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 16-34	6.1	70
302	Liver fibrosis and fatty liver in Asian HIV-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 411-21	6.1	35
301	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , <b>2016</b> , 65, 887-8	19.2	25
300	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 461-468.e2	6.9	18
299	Infection and Cancer: The Case of Hepatitis B. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 83-90	2.2	105
298	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 390-398	13.4	55
297	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 96-101	6.1	22
296	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1481-1489.e5	6.9	36

295	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1011-1019	13.4	61
294	Chronic kidney disease: Treatment of hepatitis C virus infection in patients with CKD. <i>Nature Reviews Nephrology</i> , <b>2016</b> , 12, 5-6	14.9	4
293	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , <b>2016</b> , 10, 1-98	8.8	1288
292	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. <i>Journal of Digestive Diseases</i> , <b>2016</b> , 17, 538-546	3.3	25
291	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 848-55	4	106
290	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , <b>2016</b> , 63, 754-63	11.2	68
289	Reply. <i>Hepatology</i> , <b>2016</b> , 64, 1820-1821	11.2	
288	Reply. <i>Hepatology</i> , <b>2016</b> , 64, 685-6	11.2	1
287	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2702	1.8	31
286	Virus and Host Testing to Manage Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62 Suppl 4, S298-S305	11.2	11
285	Reply. <i>Gastroenterology</i> , <b>2016</b> , 150, 1255	13.3	1
284	Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis. <i>Advances in Therapy</i> , <b>2016</b> , 33, 862-75	4.1	14
283	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 185-195	18.8	237
282	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. <i>Hepatology</i> , <b>2016</b> , 64, 1507-1517	11.2	19
281	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 196-206	18.8	259
280	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 957-966	6.1	28
279	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 56-67	18.8	103
278	Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 145-53	6.1	19

277	Letter: factors determining liver fibrosis - more to come. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 171-2	6.1	
276	Probability-based interpretation of liver stiffness measurement in untreated chronic hepatitis B patients. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 1448-56	4	16
275	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , <b>2015</b> , 64, 667-72	19.2	148
274	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , <b>2015</b> , 9, 43-51	5.8	17
273	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1306-14; quiz 1315	0.7	164
272	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , <b>2015</b> , 121, 97-108	10.8	105
271	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1086-92	13.4	37
270	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1190-7	13.4	59
269	Truncated HBx-dependent silencing of GAS2 promotes hepatocarcinogenesis through deregulation of cell cycle, senescence and p53-mediated apoptosis. <i>Journal of Pathology</i> , <b>2015</b> , 237, 38-49	9.4	25
268	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 4138-48	3.1	162
267	New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1391-6	4	69
266	Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 1190-9	6.1	7
265	Histone Deacetylase HDAC8 Promotes Insulin Resistance and $\beta$ -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma. <i>Cancer Research</i> , <b>2015</b> , 75, 4803-16	10.1	74
264	Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 199-208	6.1	41
263	Letter: pre- and post-operative anti-viral therapy is important for patients with hepatitis B virus-related hepatocellular carcinoma - authors'Reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 790	6.1	
262	Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 182-9	13.4	104
261	Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 377-385.e5	6.9	6
260	The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 328-34	3.4	22

259	Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 582-90	4	10
258	Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 731-40	6.1	46
257	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. <i>Hepatology</i> , <b>2015</b> , 62, 684-93	11.2	60
256	Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. <i>Disease Markers</i> , <b>2015</b> , 2015, 564057	3.2	62
255	A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1100-11	13.4	49
254	Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease--authorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1331-2	6.1	
253	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2599-607	59.2	758
252	Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 783-90.e1	6.9	42
251	Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 956-67	13.4	285
250	Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1040-8	4	6
249	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E1317-25	11.5	392
248	PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 139-46	4	98
247	Higher estimated net endogenous Acid production may be associated with increased prevalence of nonalcoholic Fatty liver disease in chinese adults in Hong Kong. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122406	3.7	18
246	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139310	3.7	56
245	Effect of pregnancy on the activity and infectivity of hepatitis B virus in women with chronic hepatitis B infection. <i>Hong Kong Medical Journal</i> , <b>2015</b> , 21 Suppl 7, S4-7	0.7	2
244	Viral-human chimeric transcript predisposes risk to liver cancer development and progression. <i>Cancer Cell</i> , <b>2014</b> , 25, 335-49	24.3	199
243	Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. <i>Gut</i> , <b>2014</b> , 63, 1793-804	19.2	44
242	PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 532-9	6.1	82

241	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 825-34	3.4	29
240	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , <b>2014</b> , 65, 174-86	7.3	18
239	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. <i>Hepatology</i> , <b>2014</b> , 59, 986-95	11.2	98
238	Fatty pancreas, insulin resistance, and $\beta$ -cell function: a population study using fat-water magnetic resonance imaging. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 589-97	0.7	140
237	Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. <i>Gastroenterology</i> , <b>2014</b> , 146, 1240-8	13.3	117
236	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 254-69	6.1	249
235	Liver injury is common among chronic abusers of ketamine. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1759-62.e1	6.9	36
234	Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 809-15	13.4	25
233	Hepatitis B virus infection. <i>Lancet, The</i> , <b>2014</b> , 384, 2053-63	40	930
232	Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Infectious Diseases and Therapy</i> , <b>2014</b> , 3, 191-202	6.2	7
231	A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 1714-23	11.6	71
230	Commentary: how long does one need to fast before a Fibroscan examination?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 540-1	6.1	1
229	Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 716-26	6.1	11
228	Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 197-208	6.1	47
227	One-stop clinic for ketamine-associated uropathy: report on service delivery model, patientsQ characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. <i>BJU International</i> , <b>2014</b> , 114, 754-60	5.6	33
226	Reply: To PMID 24519364. <i>Hepatology</i> , <b>2014</b> , 60, 1797-8	11.2	1
225	Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1485-93	4	4
224	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 883-93	6.1	79

223	Targeted hepatitis C screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 116-20	4	28
222	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 708-9	13.4	56
221	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 339-45	13.4	173
220	Functional significance of hepatitis B virus subgenotype Cs genomic markers. <i>Hong Kong Medical Journal</i> , <b>2014</b> , 20 Suppl 6, 28-30	0.7	
219	Non-invasive algorithm for detecting advanced liver fibrosis in chronic hepatitis B patients. <i>Hong Kong Medical Journal</i> , <b>2014</b> , 20 Suppl 6, 31	0.7	
218	Are we ready to use the hepatitis B surface antigen level to guide peginterferon treatment in HBeAg-negative chronic hepatitis B?. <i>Hepatology International</i> , <b>2013</b> , 7, 13-5	8.8	1
217	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Seminars in Cancer Biology</i> , <b>2013</b> , 23, 471-82	12.7	66
216	Association between anthropometric parameters and measurements of liver stiffness by transient elastography. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 295-302.e1-3	6.9	48
215	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28, 1842-8	4	29
214	Hepatitis B virus reactivation associated with anti-neoplastic therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28, 31-7	4	50
213	Treatment of non-alcoholic steatohepatitis with <i>Phyllanthus urinaria</i> : a randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28, 57-62	4	19
212	Peginterferon therapy for chronic hepatitis B: one size fits all?. <i>Gut</i> , <b>2013</b> , 62, 185-7	19.2	7
211	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. <i>Hepatology</i> , <b>2013</b> , 58, 1537-47	11.2	321
210	Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. <i>Gastroenterology</i> , <b>2013</b> , 144, 933-44	13.3	136
209	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 536-42	13.4	183
208	Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. <i>Radiology</i> , <b>2013</b> , 269, 910-8	20.5	218
207	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 18761-8	11.5	267
206	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28, 1762-9	4	19

205	Chronic hepatitis B: a treatment update. <i>Seminars in Liver Disease</i> , <b>2013</b> , 33, 122-9	7.3	14
204	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 2332-8	5.1	16
203	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , <b>2013</b> , 33, 298-298	7.3	
202	Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, e37-46	3.4	66
201	Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 517-26	6.1	61
200	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. <i>Hepatology</i> , <b>2013</b> , 58, 872-80	11.2	163
199	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 979-86	1.6	10
198	Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes. <i>Annals of Surgery</i> , <b>2013</b> , 257, 922-8	7.8	81
197	Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 671-9	1.6	8
196	52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. <i>PLoS ONE</i> , <b>2013</b> , 8, e54279	3.7	33
195	Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. <i>PLoS ONE</i> , <b>2013</b> , 8, e62885	3.7	205
194	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 256-262	3.1	187
193	Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1326-35	6.1	42
192	Antiviral drug resistance testing in patients with chronic hepatitis B. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 221-31	4	6
191	Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, 732-43	3.4	77
190	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 533-40	13.4	151
189	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 833-9	13.4	184
188	Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 1057-66	6.1	49

187	Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. <i>Gastroenterology</i> , <b>2012</b> , 142, 513-520.e1	13.3	134
186	Improving transient elastography performance for detecting hepatitis B cirrhosis. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 61-6	3.3	22
185	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , <b>2012</b> , 6, 531-61	8.8	768
184	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , <b>2012</b> , 32, 271-8	7.9	14
183	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , <b>2012</b> , 61, 409-15	19.2	328
182	Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1862-71	0.7	244
181	PWE-293 Low glycaemic index dietary intervention for patients with non-alcoholic fatty liver disease in the general population—randomised controlled trial. <i>Gut</i> , <b>2012</b> , 61, A417.1-A417	19.2	
180	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. <i>Gut</i> , <b>2011</b> , 60, 829-36	19.2	183
179	Data mining on DNA sequences of hepatitis B virus. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , <b>2011</b> , 8, 428-40	3	27
178	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 236-42	13.4	110
177	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 497; author reply 498	13.4	4
176	Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1121-31	13.4	237
175	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , <b>2011</b> , 12, 568-74	21.7	427
174	The G1613A mutation in the HBV genome affects HBeAg expression and viral replication through altered core promoter activity. <i>PLoS ONE</i> , <b>2011</b> , 6, e21856	3.7	22
173	On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 165-72	1.6	75
172	Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 1249-57	1.6	86
171	Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 300-5	4	109
170	JGH Foundation emerging leadership lecture. Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 8-12	4	23

169	Chronic hepatitis B in Asia-new insights from the past decade. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26 Suppl 1, 131-7	4	58
168	Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 419-20	4	3
167	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 1104-12	6.1	134
166	Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 344-52	6.1	100
165	Do we need a histological score to diagnose non-alcoholic steatohepatitis?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 494-5; author reply 495-6	6.1	3
164	Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 424-31	6.1	19
163	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 972-81	6.1	14
162	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. <i>Liver International</i> , <b>2011</b> , 31, 1047-53	7.9	27
161	Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. <i>Journal of Gastroenterology</i> , <b>2011</b> , 46, 391-400	6.9	58
160	Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. <i>Hepatology</i> , <b>2011</b> , 54, 1591-9	11.2	153
159	Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. <i>Journal of Epidemiology and Community Health</i> , <b>2011</b> , 65, 556-8	5.1	34
158	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. <i>Gut</i> , <b>2011</b> , 60, 1721-7	19.2	205
157	Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 408-14	7	91
156	Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development. <i>PLoS ONE</i> , <b>2011</b> , 6, e22888	3.7	63
155	Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 1095-103	6.1	97
154	Letters to the Editors: Potential pitfalls on the validation of liver stiffness measurement by Fibroscan with histological staging in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 937-8	6.1	1
153	Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 1059-68	6.1	39
152	Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 1323-31	6.1	89

151	Individualisation of antiviral therapy for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 1206-16	4	16
150	Transient elastography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 1726-31	4	64
149	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut</i> , <b>2010</b> , 59, 969-74	19.2	431
148	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , <b>2010</b> , 59, 277.1-277	19.2	
147	Aberrant concentrations of liver-derived plasma albumin mRNA in liver pathologies. <i>Clinical Chemistry</i> , <b>2010</b> , 56, 82-9	5.5	15
146	Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1660-5	2.2	336
145	Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 132-8	0.7	47
144	Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice. <i>Gastroenterology</i> , <b>2010</b> , 138, 694-704, 704.e1	13.3	63
143	Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. <i>Journal of Clinical Virology</i> , <b>2010</b> , 47, 193-5	14.5	12
142	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 145-55	1.6	37
141	Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed?. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 607-16	1.6	9
140	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. <i>Hepatology International</i> , <b>2010</b> , 4, 386-95	8.8	44
139	Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 3541-7	4	17
138	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2010</b> , 51, 454-62	11.2	790
137	Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. <i>Hepatology</i> , <b>2010</b> , 51, 2008-19	11.2	84
136	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , <b>2010</b> , 51, 1945-53	11.2	85
135	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. <i>Hepatology</i> , <b>2010</b> , 52, 1232-41	11.2	192
134	A magnetic bead-based serum proteomic fingerprinting method for parallel analytical analysis and micropreparative purification. <i>Electrophoresis</i> , <b>2010</b> , 31, 1721-30	3.6	17

133	Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1494-500	19.7	48
132	Multiplex detection of 60 hepatitis B virus variants by maldi-tof mass spectrometry. <i>Clinical Chemistry</i> , <b>2009</b> , 55, 1503-9	5.5	37
131	Efficacy of cap-assisted colonoscopy in comparison with regular colonoscopy: a randomized controlled trial. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 41-6	0.7	106
130	Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. <i>Journal of Clinical Microbiology</i> , <b>2009</b> , 47, 1830-6	9.7	18
129	Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus. <i>Molecular and Cellular Proteomics</i> , <b>2009</b> , 8, 2582-94	7.6	41
128	Treatment of chronic hepatitis B: focus on telbivudine. <i>Expert Review of Anti-Infective Therapy</i> , <b>2009</b> , 7, 259-68	5.5	12
127	High level virion production and surface antigen expression with 1.5 copies of hepatitis B viral genome. <i>Journal of Virological Methods</i> , <b>2009</b> , 159, 135-40	2.6	2
126	Revisiting the treatment recommendations for chronic hepatitis B. <i>Hepatology</i> , <b>2009</b> , 49, 700; author reply 701-2	11.2	7
125	Reply:. <i>Hepatology</i> , <b>2009</b> , 50, 2049-2050	11.2	3
124	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 2766-70	7.5	171
123	Lamivudine monophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 224-9	19.7	16
122	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 387-96	6.1	87
121	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 36-44	3.4	307
120	Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 63-9	4	19
119	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 1002-7	4	85
118	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 955-61	4	55
117	Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 1179-86	4	52
116	The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats. <i>Liver International</i> , <b>2009</b> , 29, 25-36	7.9	21

115	Surrogate end points and long-term outcome in patients with chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 1113-20	6.9	44
114	Antiviral therapy for chronic hepatitis B: challenges in Hong Kong. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 1088-94	5.4	11
113	High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. <i>Gastroenterology</i> , <b>2009</b> , 137, 525-31	13.3	99
112	Predictors of treatment response in chronic hepatitis B. <i>Drugs</i> , <b>2009</b> , 69, 2167-77	12.1	30
111	Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 227-33	6.9	59
110	Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 605-11	2.2	507
109	Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 1361-6	6.9	69
108	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. <i>Gut</i> , <b>2009</b> , 58, 111-7	19.2	168
107	Health-related quality of life in Chinese patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 592-8	4	13
106	Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 783-9	4	20
105	Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 914-21	4	53
104	Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 1067-77	6.1	293
103	A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 449-58	3.4	12
102	Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. <i>Asian Journal of Surgery</i> , <b>2008</b> , 31, 41-9	1.6	33
101	Comparison of EUS and ERCP in the investigation with suspected biliary obstruction caused by choledocholithiasis: a randomized study. <i>Gastrointestinal Endoscopy</i> , <b>2008</b> , 67, 660-8	5.2	93
100	Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 1022-6	6.9	23
99	Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 372, 571-7	3.4	27
98	COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 374, 175-80	3.4	33

97	A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 374, 773-6	3.4	24
96	Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 1027-35	6.9	127
95	Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1682-8	0.7	82
94	Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. <i>Journal of Virology</i> , <b>2008</b> , 82, 3604-11	6.6	60
93	Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 3071-81	0.7	73
92	Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. <i>Clinical Chemistry</i> , <b>2008</b> , 54, 1528-36	5.5	124
91	High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 177-82	2.2	242
90	A review of telbivudine for the management of chronic hepatitis B virus infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2008</b> , 4, 1351-61	5.5	9
89	Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. <i>Hepatology</i> , <b>2008</b> , 47, 473-83	11.2	32
88	Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. <i>Liver International</i> , <b>2008</b> , 28, 79-87	7.9	93
87	Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. <i>Journal of Medical Virology</i> , <b>2008</b> , 80, 591-7	19.7	44
86	Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS). <i>Antiviral Therapy</i> , <b>2008</b> , 13, 555-62	1.6	4
85	Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon 2a (40 kDa; PEGASYS®). <i>Antiviral Therapy</i> , <b>2008</b> , 13, 555-562	1.6	12
84	Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. <i>Clinical Gastroenterology and Hepatology</i> , <b>2007</b> , 5, 1462-8	6.9	271
83	Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. <i>Hepatology</i> , <b>2007</b> , 46, 315-23	11.2	33
82	Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. <i>Liver Transplantation</i> , <b>2007</b> , 13, 1228-35	4.5	47
81	Can dietetic intervention for obesity ever succeed in real life?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2007</b> , 22, 459-60	4	2
80	How should we manage patients with non-alcoholic fatty liver disease in 2007?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2007</b> , 22, 801-8	4	55

79	Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 25, 891-8	6.1	37
78	Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis. <i>Gut</i> , <b>2007</b> , 56, 991-9	19.2	33
77	Response to Drs. Navaneethan and Jayanthi. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 456-456	0.7	1
76	High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 1254-63	5.5	47
75	Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 745-54	8	148
74	Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. <i>Biochemical and Biophysical Research Communications</i> , <b>2007</b> , 356, 53-9	3.4	12
73	RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma. <i>Cancer Letters</i> , <b>2007</b> , 253, 43-52	9.9	37
72	Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. <i>Lancet, The</i> , <b>2007</b> , 369, 1621-6	4.0	239
71	Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. <i>Diabetologia</i> , <b>2006</b> , 49, 1777-84	10.3	41
70	Antiviral effect of Phyllanthus nanus ethanolic extract against hepatitis B virus (HBV) by expression microarray analysis. <i>Journal of Cellular Biochemistry</i> , <b>2006</b> , 97, 795-812	4.7	29
69	Hepatocellular carcinoma and hepatitis B virus. <i>Seminars in Liver Disease</i> , <b>2006</b> , 26, 153-61	7.3	187
68	Phylogenetic, virological, and clinical characteristics of genotype C hepatitis B virus with TCC at codon 15 of the precore region. <i>Journal of Clinical Microbiology</i> , <b>2006</b> , 44, 681-7	9.7	21
67	The molecular diagnosis of hepatitis B virus-associated hepatocellular carcinoma. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2006</b> , 43, 69-101	9.4	10
66	Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1516-23	0.7	55
65	Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 1154-61	6.9	152
64	Effect of celecoxib on experimental liver fibrosis in rat. <i>Liver International</i> , <b>2006</b> , 26, 125-36	7.9	40
63	Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 1703-11	6.1	14
62	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 1215-22	6.1	80

61	Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 328-35	5.5	114
60	Anti-proliferative and pro-apoptotic effects of herbal medicine on hepatic stellate cell. <i>Journal of Ethnopharmacology</i> , <b>2005</b> , 100, 180-6	5	56
59	Transmission of hepatitis B by human bite--confirmation by detection of virus in saliva and full genome sequencing. <i>Journal of Clinical Virology</i> , <b>2005</b> , 33, 254-6	14.5	29
58	A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. <i>Complementary Therapies in Medicine</i> , <b>2005</b> , 13, 175-82	3.5	23
57	Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. <i>Gastroenterology</i> , <b>2005</b> , 128, 1890-7	13.3	182
56	Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. <i>Gastroenterology</i> , <b>2005</b> , 128, 1845-50	13.3	80
55	A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 2205-11	0.7	28
54	Histological progression of non-alcoholic fatty liver disease in Chinese patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 21, 407-13	6.1	69
53	Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22, 519-28	6.1	36
52	Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , <b>2005</b> , 41, 1357-64	11.2	64
51	Molecular virology in chronic hepatitis B: genotypes. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , <b>2005</b> , 66, 13-6	0.8	6
50	Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 191, 2022-32	7	84
49	Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 238-44	59.2	447
48	A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. <i>Annals of Internal Medicine</i> , <b>2005</b> , 142, 240-50 <sup>8</sup>		207
47	Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 616-23	0.7	164
46	An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8041-7	2.2	34
45	Clinical significance of hepatic derangement in severe acute respiratory syndrome. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 2148-53	5.6	34
44	Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. <i>Gut</i> , <b>2004</b> , 53, 1494-8	19.2	366

43	Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monophrophylaxis. <i>Clinical Transplantation</i> , <b>2004</b> , 18, 295-300	3.8	31
42	Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19, 323-9	6.1	22
41	Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20, 45-9	6.1	42
40	Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. <i>Liver International</i> , <b>2004</b> , 24, 611-8	7.9	41
39	Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. <i>Modern Pathology</i> , <b>2004</b> , 17, 1169-79	9.8	83
38	Effect of prostaglandin E2 and prostaglandin I2 on PDGF-induced proliferation of LI90, a human hepatic stellate cell line. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>2004</b> , 71, 329-33	2.8	12
37	Impact of severe acute respiratory syndrome on liver transplantation service. <i>Transplantation Proceedings</i> , <b>2004</b> , 36, 2302-3	1.1	17
36	Absence of impact of donor hepatic steatosis and posttransplantation lamivudine resistance in a patient with chronic hepatitis B. <i>Transplantation Proceedings</i> , <b>2004</b> , 36, 2309-10	1.1	
35	Complications of liver donation for living related liver transplantation. <i>Transplantation Proceedings</i> , <b>2004</b> , 36, 2224-5	1.1	3
34	Multimodality tumor control and living donor transplantation for unresectable hepatocellular carcinoma. <i>Transplantation Proceedings</i> , <b>2004</b> , 36, 2287-8	1.1	5
33	Retrospective analysis of liver function derangement in severe acute respiratory syndrome. <i>American Journal of Medicine</i> , <b>2004</b> , 116, 566-7	2.4	17
32	A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. <i>Journal of Clinical Gastroenterology</i> , <b>2004</b> , 38, S136-43	3	27
31	A cirrhotic patient with fever and abdominal pain in the presence of ascites. <i>British Journal of Hospital Medicine</i> , <b>2003</b> , 64, 310		1
30	Adoptive immune transfer in liver transplantation of HBV-related liver diseases. <i>Hepatology</i> , <b>2003</b> , 37, 1224-5; author reply 1225	11.2	2
29	Fulminant hepatic failure in a patient with inactive HBsAg carrier state, acute hepatitis E and thyrotoxicosis. <i>Hepatology Research</i> , <b>2003</b> , 27, 248-251	5.1	7
28	Double-blinded placebo-controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 18, 339-45	6.1	16
27	Fatal outcome of SARS in a patient with reactivation of chronic hepatitis B. <i>American Journal of Medicine</i> , <b>2003</b> , 115, 334-6	2.4	4
26	Liver transplantation for hepatocellular carcinoma in cirrhotic patients-a single-center experience. <i>Transplantation Proceedings</i> , <b>2003</b> , 35, 379-80	1.1	3

25	Immunosuppression with rapid steroid reduction among predominantly HBV liver transplantation recipients: initial experience. <i>Transplantation Proceedings</i> , <b>2003</b> , 35, 419-20	1.1	1
24	Virological and histological outcome of a patient with chronic hepatitis B transplanted with liver from hepatitis C virus-positive donor. <i>Transplantation Proceedings</i> , <b>2003</b> , 35, 423-4	1.1	
23	High incidence of incidental hepatocellular carcinoma exists among hepatic explanted livers. <i>Transplantation Proceedings</i> , <b>2003</b> , 35, 350-1	1.1	10
22	Coronavirus in severe acute respiratory syndrome (SARS). <i>Trends in Molecular Medicine</i> , <b>2003</b> , 9, 323-5	11.5	26
21	Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. <i>Journal of Clinical Microbiology</i> , <b>2003</b> , 41, 1277-9	9.7	104
20	Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B. <i>Journal of Clinical Microbiology</i> , <b>2003</b> , 41, 4793-5	9.7	20
19	Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. <i>World Journal of Gastroenterology</i> , <b>2003</b> , 9, 2695-7	5.6	45
18	Icteric flare of chronic hepatitis B in a 95-year old patient. <i>World Journal of Gastroenterology</i> , <b>2003</b> , 9, 2876-7	5.6	1
17	Changing scene in hepatitis B serology interpretation. <i>British Journal of Hospital Medicine</i> , <b>2002</b> , 63, 16-9		14
16	Factors associated with viral breakthrough in lamivudine monotherapy of hepatitis B virus recurrence after liver transplantation. <i>Journal of Medical Virology</i> , <b>2002</b> , 68, 182-7	19.7	79
15	Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. <i>Journal of Viral Hepatitis</i> , <b>2002</b> , 9, 229-34	3.4	44
14	The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. <i>Journal of Viral Hepatitis</i> , <b>2002</b> , 9, 424-8	3.4	61
13	Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 251-60	6.1	28
12	Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 2629-33	0.7	26
11	Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 406-12	0.7	123
10	Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. <i>Journal of Clinical Gastroenterology</i> , <b>2002</b> , 34, 569-72	3	78
9	Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 1211-5	0.7	66
8	Eradication of <i>Helicobacter pylori</i> and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. <i>Lancet, The</i> , <b>2002</b> , 359, 9-13	40	239

7	Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2001</b> , 15, 1737-44	6.1	38
6	The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2001</b> , 15, 1899-905	6.1	54
5	Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. <i>Gastrointestinal Endoscopy</i> , <b>2001</b> , 53, 438-42	5.2	71
4	Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. <i>Hepatology</i> , <b>2000</b> , 31, 763-8	11.2	168
3	Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus infected patients. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 3547-3551	0.7	17
2	Comparison of three different sensitive assays for hepatitis B virus DNA in monitoring of responses to antiviral therapy. <i>Journal of Clinical Microbiology</i> , <b>2000</b> , 38, 3205-8	9.7	29
1	Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. <i>Hepatology</i> , <b>1999</b> , 29, 976-84	11.2	231